In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer. The study is published in the peer-reviewed ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

GLP-1: Glucagon-like peptide-1 ... GLP1-RAs result in an associated increased risk of pancreatitis or medullary thyroid carcinoma. Development of antidrug antibodies are common with the LA ...

A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients ... a family history of medullary thyroid carcinoma and multiple endocrine ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...